Sponsored
Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch.
Bansi Nagji, CEO, PANTHERx Rare
Advertisement
Articles by Bansi Nagji, CEO, PANTHERx Rare
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
5